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Idiopathic Parkinson’s disease (PD) is a progressive neuro-
degenerative disorder which affects 1 to 2% of the population 
over 60 years. The differential diagnosis between PD and atyp-
ical Parkinsonian syndromes is usually difficult in the medi-
cal practice, mainly in the beginning of clinical manifestation. 
Modern neuroimaging techniques, such as PET and SPECT, 
have proved to be useful in the clinical scenario, although ex-
pensive and inaccessible1.
Transcranial sonography (TCS) of the brain has recent-
ly emerged as a novel diagnostic test for the evaluation of 
movement disorders1,2. The authors report a patient with PD 
in whom TCS disclosed hyperechogenicity of the substantia 
nigra (SN) region; the significance of this finding (SNH) in the 
clinical practice was discussed.
CASE REPoRT
A 54-year-old female had a 16-year history of PD which 
followed a characteristic course with gradually worsening 
symptoms. Hand tremor at rest began initially on the left side 
and, after 3 years, both sides were affected. Current neurolog-
ical examination revealed an asymmetric tremor, bradykine-
sia and muscle rigidity; there were posture and balance dys-
functions, and reduction of automatic movements. Results of 
brain CT and MRI were normal. TCS of the brain parenchyma 
disclosed a SN echogenic area greater than 0.20 cm2, bilater-
ally, fulfilling the criteria for SNH (Figure). Written informed 
consent was obtained from the patient.
DiSCuSSion
SNH, visualized by TCS, has been considered a biological 
marker for PD. This ultrasound sign is found in the majority 
of PD patients (>90%) and has been demonstrated to be as-
sociated with functional impairment of the nigrostriatal dop-
aminergic system1-3.
Animal and human postmortem analyses have attrib-
uted increased iron content in the SN as a cause for the 
hyperechogenicity1,2. It is not known, however, whether in-
creased SN iron levels may cause oxidative stress and second-
ary neuronal damage or whether SN degenerative process 
leads to increased iron content in the SN region3. 
SNH is less frequently encountered in essential tremor, 
vascular parkinsonism, multiple system atrophy and pro-
gressive supranuclear palsy while this echo feature occurs 
in most PD patients1,4,5. SNH can be found in a minority of 
healthy subjects (10%) and they are more likely to develop ex-
trapyramidal signs and symptoms following administration 
of neuroleptic1,2,5.
Some factors limit the usefulness of TCS, such as its de-
pendence on the operator experience and the lack of tempo-
ral acoustic windows (about 10% of patients)1. No correlation 
Figure. Transcranial sonographic images of the midbrain. The 
butterfly-shaped midbrain and the substantia nigra region 
hyperechogenicity were encircled.
154
LETTERS
Vasculitic neuropathy following influenza 
seasonal vaccination
Neuropatia por vasculite após vacinação para influenza sazonal
Paulo J. Lorenzoni, Rosana H. Scola, Cláudia S. Kamoi Kay, Eustáquio de Queiroz, Juliana Cardoso, 
Lineu C. Werneck
Neuromuscular Disorder Service, Neurology Division, Internal Medicine Department, Hospital de Clínicas da Universidade Federal do Paraná (UFPR), Curitiba 
PR, Brazil.
Correspondence: Rosana Herminia Scola; Serviço de Doenças Neuromusculares; Hospital de Clínicas da UFPR; Rua General Carneiro 181 / 3º andar; 
80060-900 Curitiba PR - Brasil. ; E-mail: scola@hc.ufpr.br 
Conflict of interest: There is no conflict of interest to declare.
Received 02 August 2011; Received in final form 02 September 2011; Accepted 12 September 2011
Influenza seasonal vaccination is widely performed and 
clearly justified on public healthy grounds. However, neuro-
logical complications have been reported following influenza 
vaccinations1.
We describe a case of small vessel vasculitis with involve-
ment of skin and peripheral nerves after influenza seasonal 
vaccination. 
 CASE REPoRT
A 24-year-old woman presented 21 days after influenza 
seasonal vaccination arthralgias on ankles and knees associ-
ated with skin rash in the legs. Four days after initial symp-
toms, she developed parestesia in her fingers, toes and lateral 
region of right leg associated to weakness in left hand and 
right foot. 
On physical examination, she had purpuric cutaneous rash 
on both ankles and lower limbs (Fig A and B). Neurological 
examination revealed weakness in left hand and right foot, 
and diffuse reduction in deep tendon reflexes. Pain, pinprick 
and light touch were impaired distally in the arms and legs, 
more pronounced in region of left ulnar nerve and right per-
oneal nerve.
Laboratory tests, as well as serological tests, were normal. 
Electrophysiological study showed an asymmetrical sensory-
motor axonal neuropathy consistent with multiplex monon-
europathy. Skin biopsy showed leucocytoclastic vasculitic 
(Fig C). Sural nerve biopsy showed inflammatory perivascular 
infiltration in the small vessel in epineurium and a reduction 
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was found between the degree of SNH and the severity of do-
paminergic innervations impairment4; moreover, SNH seems 
not to change during the course of PD, so that the progression 
of PD cannot be monitored by TCS3.
Future longitudinal studies must address if SNH can 
help to identify PD patients at preclinical stages mainly if 
considered in conjunction with other nonmotor signs of PD, 
such as depression, olfactory dysfunction, neuropsychologi-
cal deficits and idiopathic REM sleep behavior disorder5. If 
this idea is true, PD could be identified before manifestation 
of typical signs and symptoms, allowing development of neu-
roprotective therapies1-5.
